spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  darbepoetin alfa 

 HSMN NewsFeed - 5 May 2020
Akebia Therapeutics Announces Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis
Biopharmaceuticals
 HSMN NewsFeed - 16 Feb 2010
Centocor Ortho Biotech Products and Amgen Finalize ESA Risk Evaluation and Mitigation Strategy (REMS) With FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Mar 2008
Amgen to Discuss Benefits and Risks of ESA Treatment for Cancer Patients with Anemia Due to Chemotherapy at FDA ODAC Meeting
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Mar 2008
Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa)
Biopharmaceuticals
 HSMN NewsFeed - 7 Mar 2008
Amgen Announces Update to U.S. Prescribing Information for Aranesp(R) and EPOGEN(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Mar 2008
EU Commission Approves Updated Prescribing Information for Aranesp(R)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Dec 2007
NCCN Updates Cancer- and Treatment-Related Anemia Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Nov 2007
Amgen Announces Updates to the U.S. Prescribing Information for ESAs
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Oct 2007
Jury Rules Roche Infringes Amgen's EPO Patents
Biopharmaceuticals Litigation
 HSMN NewsFeed - 27 Sep 2007
Amgen Receives Proposal for Amending EU Prescribing Information for Aranesp(R)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 25 Sep 2007
Aranesp(R) DAHANCA 10 Study Results Presented at ECCO Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Sep 2007
Amgen to Review Benefits, Risks of ESA Therapy in Chronic Renal Failure Patients at FDA Advisory Committee
Biopharmaceuticals
 HSMN NewsFeed - 6 Sep 2007
Aranesp(R) Study Showing No Negative Impact on Survival in SCLC Presented at World Conference on Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Aug 2007
Amgen Restructures Due to Lower Aranesp(R) Revenues While Continuing to Invest in Innovation and Future Growth
Biopharmaceuticals
 HSMN NewsFeed - 16 Jul 2007
Affymax(R) Announces Phase 3 Development Plan for Hematide(TM)
Biopharmaceuticals
 HSMN NewsFeed - 19 Apr 2007
Aranesp(R) ``145 Study'' Shows No Difference in Survival in Patients with Small-Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Apr 2007
Aranesp(R) Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Apr 2007
Data Analyses Outline Efficacy and Safety of MIRCERA(TM) for the Treatment of Renal Anemia Associated With Chronic Kidney Disease
Biopharmaceuticals
 HSMN NewsFeed - 9 Mar 2007
Amgen Announces Update To U.S. Prescribing Information for Aranesp(R) and EPOGEN(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Mar 2007
NCCN Updates Cancer- and Treatment-Related Anemia Guidelines
Oncology
 HSMN NewsFeed - 26 Feb 2007
NCCN Updates Myelodysplastic Syndromes (MDS) Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Feb 2007
Fresenius Medical Care and Amgen Enter New Commercial Collaboration in Europe
Biopharmaceuticals
 HSMN NewsFeed - 15 Dec 2006
Roche Offers the FDA Additional MIRCERA(R) Data
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Oct 2006
Study Evaluates Real-World Dosing and Cost Considerations for PROCRIT(R) (Epoetin Alfa) and Darbepoetin Alfa in the Inpatient Hospital Setting
Biopharmaceuticals
 HSMN NewsFeed - 20 Oct 2006
U.S. District Court Denies Roche Motion to Dismiss Amgen Patent Infringement Lawsuit
Biopharmaceuticals Litigation
 HSMN NewsFeed - 19 Oct 2006
Fresenius Medical Care Announces New Sourcing and Supply Agreement with Amgen
Biopharmaceuticals
 HSMN NewsFeed - 13 Oct 2006
Amgen Receives Complete Response Letter for Extended Dosing of Aranesp(R) for Patients with Chronic Kidney Disease and Anemia
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Sep 2006
Amgen Launches Aranesp(R) (Darbepoetin Alfa) Prefilled SureClick(TM) Autoinjector for Treatment of Anemia Associated with Chemotherapy and Chronic Kidney Disease
Biopharmaceuticals
 HSMN NewsFeed - 16 Jul 2006
C.E.R.A. Anti-Anemia Drug Maintained Stable Hemoglobin Levels in Dialysis Patients With Up to Once Every Four Week Dosing in Phase III Clinical Studies
Biopharmaceuticals
 HSMN NewsFeed - 16 Jul 2006
Amgen Announces EVOLVE Trial(TM) To Investigate Impact of Sensipar(R)/Mimpara(R) (cinacalcet HCl) on Mortality and Cardiovascular Morbidity in Secondary Hyperparathyroidism Patients With Chronic Kidney Disease Receiving Dialysis
Biopharmaceuticals
 HSMN NewsFeed - 18 May 2006
Large Head-to-Head Study of Aranesp(R) Dosed Every Two Weeks versus Epoetin Alfa Dosed Weekly Published in the Journal of Clinical Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 May 2006
ITC Accepts Amgen's Complaint to Investigate Roche's Importation of Peg-EPO
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 30

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 30 additional stories matching:
darbepoetin alfa
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.